Table 1.

Classes of selected kinase inhibitors^26,28.

Class	Mechanism of action	Examples
Type I	Binding in the ATP-binding pocket of the active conformation of the enzyme (DFG-in and αC-helix-in)	cabozantinib, ceritinib, gefitinib, palbociclib, pazopanib, ponatinib, ruxolitinib, tofacitinib
Type I1/2 Type II	Binding in the ATP-binding pocket of the inactive conformation of the enzyme (type I1/2: DFG-Asp in; type II: DFG-Asp out)	dasatinib, imatinib, lapatinib, lenvatinib, nilotinib, regorafenib, sorafenib, sunitinib, vemurafenib
Type III Type IV	Allosteric inhibitors binding to a site in the kinase domain either next to the ATP-binding pocket or remote from the ATP-binding pocket	trametinib, everolimus, sirolimus, temsirolimus
Type V	Bivalent inhibitors that bind two different portions of the kinase lobe	lenvatinib28
Type VI	Covalent inhibitors	afatinib, ibrutinib

In Ref. ²⁶, lenvatinib is classified as a type I^1/2 inhibitor.